Laurus Labs inks pact to buy majority stake in Richcore LifesciencesIllustrative image – not actual.
Drug firm Laurus Labs has signed definitive agreements with Eight Roads Ventures, VenturEast Proactive Fund and VenturEast Life Fund-III to acquire 72.55 percent stake in Richcore Lifesciences for Rs 246.67 crore.

The acquisition marks the company's entry into the broader biologics and biotechnology segments, providing access to its high growth areas, globally and in India.

Following the successful closure of the transaction, Richcore Lifesciences will be renamed as Laurus Bio.

Laurus Labs will fund the acquisition from its internal accruals and this acquisition will be revenue and PAT accretive.

← All latest storiesBack to top →